Application: No. 09/850,363 Filing Date: May 7, 2001

Docket No.: 294-100

Page 5

REMARKS

Applicants have undertaken to cancel claims 9-13, amend claims 1-3, 5, 6, and add new claims 14-18 in the above-identified application in order to remove improper multiple dependencies and conform to U.S. practice. No new matter has been added. In addition, headings have been added to the specification. Accordingly, entry hereof and examination on the merits are respectfully requested.

Respectfully submitted,

Lauren T. Emr

Registration No. 46,139 Attorney for Applicant(s)

HOFFMANN & Baron, LLP 6900 Jericho Turnpike Syosset, NewYork 11791 (516) 822-3550 LTE/sp

137226

Application: No. 09/850,363 Filing Date: May 7, 2001

Docket No.: 294-100

Page 6

VERSION OF AMENDMENT WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 1, before line 1, please insert the following before the first paragraph:

BACKGROUND OF THE INVENTION

On page 3, line 23, please insert the following:

SUMMARY OF THE INVENTION

On page 5, line 3, please inset the following:

DETAILED DESCRIPTION OF THE INVENTION

IN THE CLAIMS:

Please amend claims 1-3, 5, 6 as follows:

1. (Amended) A real-time test system comprising at least one reservoir and at least

one photomultiplier detector; said reservoir comprising [with] monoclonal anti-

insulin or anti-C peptide capture antibodies solidified in said reservoir, and said

[which] reservoir [is] capable of receiving [to receive] a sample, a wash solution,

and labeled [labelled] monoclonal anti-insulin or anti-C peptide antibodies useful

as a tracer, wherein said labeled antibodies allow [the label allows] photometrical

detection; [and at least one photomultiplier detector].

Application: No. 09/850,363 Filing Date: May 7, 2001 Docket No.: 294-100

Page 7

- (Amended) A test system according to claim 1, wherein the <u>labeled</u> [labelled]
 monoclonal anti-insulin or anti-C peptide <u>antibodies are</u> [is] present in dried form
 in [the] said reservoir.
- 3. (Amended) A test system according to claim 1, wherein [the] said <u>labeled</u> [labelled] monoclonal anti-insulin or anti-C peptide antibodies are <u>labeled</u> [labelled] by a chemiluminescent label.
- 5. (Amended) A method for determining insulin levels in a sample, comprising:

 adding the sample to a reservoir with monoclonal anti-insulin or anti-C

 peptide capture antibodies solidified in said reservoir; [and]

<u>adding labeled</u> [labelled] monoclonal anti-insulin or anti-C peptide antibodies useful as a tracer;

<u>incubating said reservoir to produce</u> [followed by incubation giving]

<u>labeled</u> [labelled] insulin complexes;

washing <u>said reservoir</u>; and detecting the <u>labeled</u> [labelled] insulin complexes photometrically.

6. (Amended) The method of claim 5, wherein the sample is perfusion solution obtained from a pancreas removed from a [the] body after stimulating said pancreas with an insulin-production influencing compound, preferably glucose.